Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-11-13
2002-10-22
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S364000
Reexamination Certificate
active
06469007
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to novel piperazine derivatives, to their use and to pharmaceutical compositions containing them. The novel compounds are useful as 5-HT
1A
binding agents, particularly as 5-HT
1A
receptor antagonists.
BACKGROUND
U.S. Pat. No. 6,127,357 discloses compounds of the general formula (I):
and pharmaceutically acceptable acid addition salts thereof wherein:
A is alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,
Z is oxygen or sulfur,
R is H or lower alkyl,
R
1
is a mono or bicyclic aryl or heteroaryl radical,
R
2
is a mono or bicyclic heteroaryl radical, and
R
3
is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula—NR
4
R
5
[where R
4
is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R
5
is hydrogen, lower alkyl, —CO(lower)alkyl, aryl, —Coaryl, aryl(lower)alkyl, cycloalkyl, or cycloalkyl-(lower)alkyl or R
4
and R
5
together with the nitrogen atom to which they are both attached represent a saturated hytrocyclic ring which may contain a further heteroatom], or a group of formula OR
6
[where R
6
is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl(lower)alkyl].
WO 97/03982 discloses compounds of the general formula (II):
including enantiomers and the pharmaceutically acceptable acid addition salts thereof.
The compounds of formula (II) fall within the disclosure of U.S. Pat. No. 6,127,357 but are not specifically disclosed therein. Compounds of Formula II were taught to have potent 5-HT
1A
antagonist activity in vivo when administered by the oral route.
DETAILED DESCRIPTION OF THE INVENTION
Novel compounds of the invention have the structural formula (III):
wherein R
1
is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.
Halogen, as used herein, refers to chlorine, fluorine, bromine and iodine.
The compounds of Formula III contain an asymmetric carbon atom. Accordingly, they may exist in different stereoisomeric forms. In some preferred embodiments the R stereoisomer (Formula III
a
) is preferred.
In accordance with some embodiments of the invention, the (R) stereoisomer is substantially free of the (S) stereoisomer. Substantially free, as used herein means that the compound is made up of a significantly greater proportion of its (R) stereoisomer than the (S) stereoisomer. In preferred embodiments the compound is made up of at least about 90% by weight of its (R) stereoisomer and about 10% by weight or less of its (S) stereoisomer. In other embodiments of the invention, the compound is made up of at least about 99% by weight of its (S) stereoisomer and about 1% by weight or less of the (R) stereoisomer. Preferred stereoisomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts. See, for example, Jacques, et al., Enantiomerss Racemates and Resolutions (Wiley lnterscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, N.Y. 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IND. 1972).
The most preferred compounds of the invention are (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide; and pharmaceutically acceptable acid addition salts thereof.
The pharmaceutically acceptable salts are the acid addition salts which can be formed from a compound of the above general formula and a pharmaceutically acceptable acid such as, for example, benzoic, phosphoric, sulfuric, hydrochloric, hydrobromic, citric, maleic, malic, mandelic, mucic, nitric, fumaric, succinic, tartaric, acetic, lactic, pamoic, pantothenic, benzenesulfonic, or methanesulfonic acid. In some embodiments of the invention the preferred acid addition salt is hydrochloric acid.
The compounds of the present invention can be prepared by known methods from known starting materials which are available by conventional methods. For example the compounds may be prepared by the general methods disclosed in EP-A-0512755 and WO 97/03982.
Such disclosed methods include acylating an amine of formula (IV) with a known benzoyl chloride (V) or an alternative acylating derivative thereof. Examples of acylating derivatives include the acid anhydride, imidazolides (e.g. obtained form carbonyldiimidazole), or activated esters.
wherein R
1
is cyano, halogen, trifluoromethyl or nitro.
Novel compounds of the present invention are potent 5-HT
1A
binding agents which selectively binds to the 5-HT
1A
receptor. Furthermore, the novel compounds of the invention are 5-HT
1A
receptor antagonists when tested by standard pharmacological procedures.
In addition, the novel compounds of formula (III) are unique from previously disclosed 5HT
1A
receptor antagonists in that they possess a superior duration of action as a 5-HT
1A
receptor antagonist when administered in vivo.
REFERENCES:
patent: 6127357 (2000-10-01), Cliffe et al.
patent: WO 97/03982 (1997-02-01), None
Robichaud et al. in “Annual Reports in Medicinal Chemsitry”, vol. 35, pp. 11-20 (2000).*
Van Steen B. J. et al: “Structure-Affinity Relationship Studies on 5-HT1A receptor Ligands 2. Heterobicyclic Phenylpiperazines with N4-Aralkyl Substituents”.
Childers Wayne E.
Kelly Michael G.
Rosenzweig-Lipson Sharon J.
Barrett Rebecca R.
Bernhardt Emily
Wyeth
LandOfFree
Serotonergic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serotonergic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serotonergic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2939543